Evidence map›Paper›PMID 42093985›Full record

ArticleFrontiers in immunology2026

Mast cell release of TNF-α indirectly contributes to recalling B cells in the colorectal cancer milieu through the CCL20/CCR6 axis.

Viviana Valeri, Francesca Mion, Silvia Tonon, Eleonora Martinis, Elena Jachetti, Roberta Sulsenti, Eleonora Capezzali, Serena Battista, Alessandro Mangogna, Laura Mariuzzi and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Viviana ValeriImmunology Section, Department of Medicine, University of Udine, Udine, Italy.
Francesca MionImmunology Section, Department of Medicine, University of Udine, Udine, Italy.
Silvia TononImmunology Section, Department of Medicine, University of Udine, Udine, Italy.
Eleonora MartinisImmunology Section, Department of Medicine, University of Udine, Udine, Italy.
Elena JachettiMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Roberta SulsentiMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Eleonora CapezzaliImmunology Section, Department of Medicine, University of Udine, Udine, Italy.
Serena BattistaPathology Department, Santa Maria della Misericordia Hospital, Udine, Italy.
Alessandro MangognaInstitute of Pathology, University Hospital of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
Laura MariuzziInstitute of Pathology, University Hospital of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
Marco FontanotInstitute of Pathology, University Hospital of Udine, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
Beatrice BelmonteDepartment of Health Science, Tumor Immunology Unit, Human Pathology Section, Palermo University School of Medicine, Palermo, Italy.
Valeria CancilaDepartment of Health Science, Tumor Immunology Unit, Human Pathology Section, Palermo University School of Medicine, Palermo, Italy.
Claudio TripodoAdvanced Pathology Laboratory, Istituto Fondazione di Oncologia Molecolare ETS (IFOM ETS)-The AIRC Institute of Molecular Oncology, Milan, Italy.
Marta MozzonGeneral Surgery, University Hospital of Udine, ASUFC, Udine, Italy.
Alessandro UzzauDepartment of Medicine, University of Udine, Udine, Italy.
Barbara FrossiImmunology Section, Department of Medicine, University of Udine, Udine, Italy.
Carlo PucilloImmunology Section, Department of Medicine, University of Udine, Udine, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In colorectal cancer (CRC), mast cells (MCs) modulate tumor and immune cell interactions, influencing patient prognosis, though their role remains not fully elucidated. Our group previously uncovered that in the intestine MCs provide support for the effector functions of B cells, both in physiology and inflammation. Methods: In this work we investigated the relationship between the activation of MCs in CRC and recruitment and accumulation of B cells in the tumor environment. Results: We observed infiltration of both B cells and MCs in the tumor tissue and uncovered accumulation of CCR6 Discussion: The accumulation of CCR6

Indexed as

B-LymphocytesChemokine CCL20Colorectal NeoplasmsMast CellsReceptors, CCR6Tumor Necrosis Factor-alphaAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred C57BLTumor MicroenvironmentCCL20 protein, humanCCL20 protein, mouseCCR6 protein, humanCCR6 protein, mouseChemokine CCL20Receptors, CCR6Tumor Necrosis Factor-alphaB cellsCCL20colorectal cancerlymph nodesmast cellsTNF-α

Identifiers

PMID42093985
PMCPMC13139354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.